

JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM

VOLUME 14, NUMBER 8

SEPTEMBER-OCTOBER 2001

TABLE OF CONTENTS

REVIEWS

- Doping with GH**
M. Bidlingmaier, Z. Wu, and C.J. Strasburger, *Munich, Germany* 1077
- Intrauterine Diabetic Environment Confers Risks for Type 2 Diabetes Mellitus and Obesity in the Offspring, in Addition to Genetic Susceptibility**
D. Dabelea and D.J. Pettitt, *Timisoara, Romania and Santa Barbara, CA, USA* 1085

ORIGINAL CONTRIBUTIONS

- Variable Presentation of X-linked Adrenal Hypoplasia Congenita**
E. Wiltshire, J. Couper, C. Rodda, J.L. Jameson and J.C. Achermann, *Adelaide and Clayton, Vic., Australia and Chicago, IL, USA* 1093
- Sustained Benefits of Growth Hormone on Body Composition, Fat Utilization, Physical Strength and Agility, and Growth in Prader-Willi Syndrome are Dose-Dependent**
A.L. Carrel, S.E. Myers, B.Y. Whitman and D.B. Allen, *Madison, WI and St. Louis, MO, USA* 1097
- Insufficient Adrenarche in Patients with Combined Pituitary Hormone Deficiency Caused by a PROP-1 Gene Defect**
A. Voutetakis, S. Livadas, A. Sertedaki, M. Maniati-Christidi and C. Dacou-Voutetakis, *Athens, Greece* 1107
- Syndrome of Congenital Adrenocortical Unresponsiveness to ACTH. Report of Six Patients**
M. Berberoğlu, Z. Aycan, G. Öcal, M. Begeot, D. Naville, N. Akar, P. Adiyaman, O. Evliyaoglu and A. Penhoat, *Ankara, Turkey and Lyon, France* 1113
- Maternal and Fetal Serum Insulin-like Growth Factor-I (IGF-I), IGF Binding Protein-3 (IGFBP-3), Leptin Levels and Early Postnatal Growth in Infants Born Asymmetrically Small for Gestational Age**
Z. Orbak, Ş. Darcan, M. Çoker and D. Gökşen, *Erzurum and Izmir, Turkey* 1119
- Relationship Between Levels of Leptin and Hematologic Parameters in Healthy Term Infants**
E. Koç, A. Bideci, P. Cinaz, E. Ergenekon and Y. Atalay, *Ankara, Turkey* 1129
- Recombinant Growth Hormone Treatment in Short Patients with Thalassemia Major: Results after 24 and 36 Months**
L. Cavallo, A. Acquafredda, C. Zecchino, V. De Sanctis, M. Cisternino, M. Caruso Nicoletti, M. Galati and F. Massolo, *Bari, Pavia, Catania, Catanzaro and Modena, Italy* 1133
- Assessment of the Current Status of Iodine Prophylaxis in Bosnia and Herzegovina Federation**
H. Tahirović, A. Toromanović, N. Hadžibegić, D. Štimljanin, R. Konjević, Z. Budimić, H. Čengi, Ž. Rončević, E. Denjo, J. Huskić, I. Hadžimujić, D. Moro, A. Ivanković, N. Dodik and S. Hasanbegović, *Tuzla, Bihać, Orašje, Goražde, Mostar, Livno, Travnik, Grude, Široki Brijeg, Ljubuški and Sarajevo, Bosnia and Herzegovina* 1139
- Profiles of Obese Children Presenting for Metabolic Evaluation**
J. Anavian, D.J. Brenner, P. Fort and P.W. Speiser, *New York, USA* 1145
- PATIENT REPORTS**
- Effect of Growth Hormone Treatment on Hypoglycemia in a Patient with both Hepatic Glycogen Synthase and Isolated Growth Hormone Deficiencies**
P. Blümel and P.E. Mullis, *Vienna, Austria and Bern, Switzerland* 1151
- Gliclazide-Induced Hepatitis, Hemiplegia and Dysphasia in a Suicide Attempt**
H. Çaksen, M. Kendirci, A. Tutuş, K. Üzümlü and S. Kurtoglu, *Van and Kayseri, Turkey* 1157
- Neonatal Goiter Caused by Expectorant Usage**
I. Bostancı, A. Sarioğlu, H. Ergin, A. Akşit, M. Cinbiş and N. Akalın, *Denizli, Turkey* 1161
- Idiopathic Hypothalamic Dysfunction with Precocious Puberty and Adipsic Hypernatremia First Presenting in Adolescence**
M.S. Cauble, L. Mack-Shipman, G.B. Schaefer, S. Balakrishnan and J.L. Larsen, *Omaha, NE, USA* 1163
- Neonatal Hyperthyroidism in Infants of Mothers Previously Thyroidectomized due to Graves' Disease**
M^oV. Borrás-Pérez, D. Moreno-Pérez, A. Zuasabar-Cotro and J.P. López-Siguero, *Barcelona and Malaga, Spain* 1169
- Primary Hyperparathyroidism in an Infant with Three Parathyroid Glands and Pulmonary Calcinosis**
A.K. Topaloglu, B. Yuksel, R. Tuncer, N.O. Mungan and G. Ozer, *Adana, Turkey* 1173
- Asymmetric Crying Facies and Congenital Hypothyroidism: Report of Two Patients**
S. Kurtoglu, H. Çaksen, H. Per, N. Narin and K. Üzümlü, *Kayseri and Van, Turkey* 1177
- Obituary: Prof. Dr. Prader (1919-2001)** 1183
- FORUM AND CORRESPONDENCE** 1185
- CALENDAR** 1187

SUPPLEMENT 4

- Abstracts of the 13th National Meeting of the Italian Society for Pediatric Endocrinology and Diabetology (SIEDP), October 2001** 1189


Indexed or abstracted by:	BIOSIS, CABS, Current Contents/Life Sciences, EMBASE/Excerpta Medica, Index Medicus, Research Alert and Science Citation Index
---------------------------	--

The Norditropin® SimpleXx® system

somatropin (epi)

- preferred by patients^{1,2}

81.5% of patients preferred the Norditropin® SimpleXx® system in comparison to three other growth hormone therapies²



94.4% of patients preferred the Norditropin® SimpleXx® system to Nutropin AQ²

80% of patients preferred the Norditropin® SimpleXx® system to Humatrope²

71.4% of patients preferred the Norditropin® SimpleXx® system to Genotropin²

Norditropin® SimpleXx®. Presentations: Norditropin® SimpleXx® 5 mg/1.5 ml, 10 mg/1.5 ml and 15 mg/1.5 ml solution for injection for use with NordiPen® 5, 10 and 15 respectively. 1 mg of somatropin corresponds to 3IU (International Units) of somatropin. **Indications:** *Children:* Growth failure due to growth hormone insufficiency. Growth failure in girls due to gonadal dysgenesis (Turner's Syndrome). Growth retardation in prepubertal children due to chronic renal disease. *Adults:* Pronounced growth hormone deficiency in known hypothalamic-pituitary disease demonstrated by two provocative tests. Childhood onset growth hormone insufficiency, reconfirmed by two provocative tests. **Dosage and Method of Administration:** The dosage is individual and must be adjusted in accordance with the individual's response to therapy. Daily subcutaneous administration in the evening is recommended. *Children:* Growth hormone insufficiency 25-35 µg/kg/day or 0.7-1.0 mg/m²/day. Turner's Syndrome 50 µg/kg/day or 1.4 mg/m²/day. Chronic Renal Disease 50 µg/kg/day or 1.4 mg/m²/day. *Adults:* Replacement therapy in adults. It is recommended to start treatment with a low dose 0.15-0.3 mg/day. Maintenance dosage seldom exceeds 1.0 mg/day. **Contra-indications:** Active tumour, tumour therapy. Treatment should be discontinued if tumour reoccurs and at renal transplantation in children treated for chronic renal disease. Currently there is insufficient evidence of safety of somatropin therapy during pregnancy. **Warnings and Precautions:** Children treated with Norditropin® SimpleXx® should be regularly assessed by a specialist in child growth. The stimulation of skeletal growth in children can only be expected until the epiphyseal discs are closed. Treatment should be instigated by a physician with special knowledge of growth hormone insufficiency. Monitor for glucose intolerance, thyroid function, renal function in patients with chronic renal insufficiency; and in patients with history of intracranial lesion for tumour progression or recurrence. Leukaemia has been reported in a small number of growth hormone deficient patients some of whom have been treated with somatropin. Based on 10 years global assessment there is no increased risk of development of leukaemia during somatropin treatment. Slipped capital femoral epiphysis and Legg-Calve-Perthes disease may occur. In the event of severe or recurrent headache, visual problems, nausea, and/or vomiting, a fundoscopy for papilloedema is recommended. If papilloedema is confirmed, a diagnosis of benign intracranial hypertension should be considered and if appropriate the growth hormone treatment should be discontinued. Growth hormone deficiency in adults is a lifelong disease and needs to be treated accordingly, however, experience in patients older than 60 years and in patients with more than five years of treatment in adult growth hormone deficiency is still limited. **Undesirable Effects:** Fluid retention with peripheral oedema may occur. The symptoms are usually transient and dose dependent, but may require dose reduction. Carpal tunnel syndrome, mild arthralgia, muscle pain and paresthesia may also occur in adults. Adverse reactions in children are rare although headache has been reported. Formation of antibodies directed against somatropin has rarely been observed. Local injection site reactions may occur. Some rare cases of benign intracranial hypertension have been reported. **Pricing and Marketing Authorisation numbers:** Norditropin® SimpleXx®, 5 mg/1.5 ml: £117.10- PL3132/0131 Norditropin® SimpleXx®, 10 mg/1.5 ml: £234.20- PL3132/0132 Norditropin® SimpleXx®, 15 mg/1.5 ml: £351.30- PL3132/0133 **Legal Category:** POM.CD4 **Date of Preparation:** June 2001, **Reference:** 1. Richard Stanhope, et al. *Journal of Paediatric Endocrinology and Metabolism*, Vol.14, No.6, pp735-740. **Reference:** 2. Shine, et al. Abstract presented at Pediatric Endocrine Nursing Society (PENS) 14th Annual Conference, San Diego, CA April 2001. Further information is available on request from: Novo Nordisk Ltd., Broadfield Park, Brighton Rd., Crawley, West Sussex RH11 9PT. Tel. No. 01293 613555. Fax No. 01293 613535. E-mail novocare@novo.dk **novo nordisk**

NORDITROPIN®
simplexx
somatropin (epi)

Humatrope is a registered trademark of Eli Lilly and Company. Nutropin AQ is a registered trademark of Genentech, Inc. Genotropin is a registered trademark of Pharmacia corporation.